GlassScriptPhysician profile
Ilene J Goldstein
NPI 1225117138
$6,265.20
in general payments reported to CMS, 2019-2025
24 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,776 · 2020: $108 · 2022: $54.20 · 2023: $522 · 2024: $851 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,746.92 | 2019-2024 | |
| Genzyme Corporation | $531.01 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $364.77 | 2022-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $187.36 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $162.30 | 2022-2025 | Nemluvio |
| Adma Biomanufacturing LLC | $151.30 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $144.63 | 2023-2024 | Tezspire, Flumist Quadrivalent |
| Alk-Abello, INC | $143.60 | 2020-2025 | Grastek, Ragwitek, Odactra |
| X4 Pharmaceuticals, INC. | $135.00 | 2024 | Xolremdi |
| Csl Behring | $125.00 | 2025 | Andembry |
| Amgen INC. | $117.93 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $116.33 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $99.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.96 | 2024 | Takhzyro |
| Sanofi-Aventis U.S. LLC | $31.11 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $26.28 | 2025 | Dawnzera |
| Biomarin Pharmaceutical INC. | $24.57 | 2025 | Voxzogo 1.2mg |
| Pharming Healthcare, INC. | $23.56 | 2024 | Ruconest |
| Glaxosmithkline, LLC. | $22.33 | 2024 | Nucala |
| Cranial Technologies, INC | $19.96 | 2025 | Doc Band |
| Tris Pharma INC | $19.53 | 2025 | Dyanavel Xr |
| Aimmune Therapeutics, INC. | $17.14 | 2022 | |
| Genentech USA, INC. | $11.92 | 2019 | |
| Kaleo, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilene Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.